Jakubowiak on Responses in Subgroups of Patients With Myeloma Who Received Cilta-Cel

Video

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

In an interview with CancerNetwork® at the 63rd American Society of Hematology Annual Meeting & Exposition, Andrzej Jakubowiak, MD, PhD, director of the Myeloma Program at University of Chicago Medicine, talked about different efficacy end points achieved with the use of ciltacabtagene autoleucel (cilta-cel) across subgroups of patients with relapsed/refractory multiple myeloma, data for which was derived from the phase 1/2b CARTITUDE-1 trial (NCT03548207).

Transcript:

The overall response rate was close to 100% and stringent complete response was 82%. MRD [minimal residual disease] rates were also in this range, specifically 92% in evaluable patients. I would start to answer this question by indicating that when we did the subgroup analysis, we looked at subgroups as follows: patients over 65, African Americans and Black, 3 and more than 4 lines of therapy, triple-class refractory, penta-drug refractory, [high] cytogenetic risks, ISS [International Staging System] stage 3, baseline bone marrow involvement of different [ranging from less than] 30% or more than 60%, BCMA [B-cell maturation antigen] expression, and presence of soft tissue plasmacytoma. These were the categories which we specifically analyzed in this context. The most important finding is that across all of these categories, response rates were almost identical, with this high 90% to 100% range. That’s an extremely important observation.

What we noted were some subtle differences in duration of response, progression-free survival, and overall survival, which trended slightly lower. Groups of patients with extramedullary plasmacytoma who had higher cytogenetics and were International Staging System 3 [had low responses], enough that we indicated in our conclusions that while these are maybe performing not as well as another groups, they still clearly outperform [on cilta-cel compared with] anything that we have available for this group of patients. That is an important observation. We see [across] all treatment modalities in myeloma that those patients may [experience] lower efficacy. Here, we have the same response rate, but indeed, there is a difference for duration response, progression-free survival, and overall survival.

Reference

Jakubowiak A, Usmani SZ, Berdeja J, et al. Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. Blood. 2021;138(suppl 1):3938. doi:10.1182/blood-2021-146069

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content